Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 328
- Registration Number
- NCT01609153
- Locations
- 🇩🇪
LWL-Klinik Dortmund, Dortmund, Germany
🇩🇪Zentrum für Seelische Gesundheit Kreiskliniken Darmstadt-Dieburg Standort: Groß-Umstadt, Groß-Umstadt, Germany
🇩🇪Universitätsmedizin Mainz Klinik für Psychiatrie und Psychotherapie, Mainz, Germany
A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics
- Conditions
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT01607762
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 101
- Registration Number
- NCT01539733
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
🇳🇱Spaarne Hospital, Hoofddorp, Netherlands
Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 48
- Registration Number
- NCT01503424
- Locations
- 🇮🇳
Lambda Therapeutic Research Ltd.,, Ahmedabad, Gujrat, India
Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 48
- Registration Number
- NCT01503398
- Locations
- 🇮🇳
Lambda Therapeutic Research Ltd.,, Ahmedabad, Gujrat, India
An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 42
- Registration Number
- NCT01498770
Metabolic Effects of Olanzapine in Healthy Males
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 24
- Registration Number
- NCT01496183
- Locations
- 🇺🇸
Department of Psychiatry, The State University of New York at Buffalo, Buffalo, New York, United States
Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation
- Conditions
- Interventions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 120
- Registration Number
- NCT01485692
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto, USP, Ribeirão Preto, São Paulo, Brazil
Bergen Psychosis Project 2 - The Best Intro Study
- Conditions
- Interventions
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 151
- Registration Number
- NCT01446328
- Locations
- 🇳🇴
Stavanger University Hospital, Stavanger, Norway
🇦🇹Medizinische Universität Innsbruck, Innsbruck, Austria
🇳🇴Haukeland University Hospital, Bergen, Norway
A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2011-07-08
- Lead Sponsor
- Shalvata Mental Health Center
- Target Recruit Count
- 2
- Registration Number
- NCT01389908
- Locations
- 🇮🇱
Shalvata MHC, Hod hasharon, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.